Cyclerion Therapeutics Inc (CYCN) - Total Liabilities
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has total liabilities worth $900.00K USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CYCN cash flow conversion to assess how effectively this company generates cash.
Cyclerion Therapeutics Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Cyclerion Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Cyclerion Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Turmalina Metals Corp
V:TBX
|
Canada | CA$1.58 Million |
|
Spring Art Holdings Bhd
KLSE:0216
|
Malaysia | RM17.85 Million |
|
Straker Ltd
AU:STG
|
Australia | AU$5.89 Million |
|
Schweizer Electronic AG
F:SCE
|
Germany | €93.41 Million |
|
Smith Micro Software Inc
NASDAQ:SMSI
|
USA | $7.24 Million |
|
Zantat Holdings Berhad
KLSE:0301
|
Malaysia | RM28.33 Million |
|
Pursuit Minerals Ltd
AU:PUR
|
Australia | AU$635.60K |
|
Avecho Biotechnology Limited
F:OEZ
|
Germany | €1.73 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Cyclerion Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cyclerion Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cyclerion Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual total liabilities of Cyclerion Therapeutics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $900.00K | +24.14% |
| 2024-12-31 | $725.00K | -65.24% |
| 2023-12-31 | $2.09 Million | -72.65% |
| 2022-12-31 | $7.63 Million | -31.20% |
| 2021-12-31 | $11.09 Million | -80.16% |
| 2020-12-31 | $55.88 Million | -37.03% |
| 2019-12-31 | $88.75 Million | +397.30% |
| 2018-12-31 | $17.85 Million | +27.14% |
| 2017-12-31 | $14.04 Million | +31.98% |
| 2016-12-31 | $10.64 Million | -- |
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a sy… Read more